In a previous report, we demonstrated that ginsenoside Rc, one of major ginsenosides from Panax ginseng, enhances γ-aminobutyric acid (GABA) receptor A (GABA A )-mediated ion channel currents. However, little is known about the effects of ginsenoside metabolites on GABA A receptor channel activity. The present study investigated the effects of ginsenoside metabolites on human recombinant GABA A receptor (α 1 β 1 γ 2s ) channel activity expressed in Xenopus oocytes using a two-electrode voltage clamp technique. M4, a metabolite of protopanaxatriol ginsenosides, more potently inhibited the GABA-induced inward peak current (I GABA ) than protopanaxadiol (PPD), a metabolite of PPD ginsenosides. The effect of M4 and PPD on I GABA was both concentration-dependent and reversible. The half-inhibitory concentration (IC 50 ) values of M4 and PPD were 17.1±2.2 and 23.1±8.6 µM, respectively. The inhibition of I GABA by M4 and PPD was voltage-independent and non-competitive. This study implies that the regulation of GABA A receptor channel activity by ginsenoside metabolites differs from that of ginsenosides.
INTRODUCTION
Gamma-aminobutyric acid (GABA) receptor A (GA-BA A ) receptors are members of the large 'Cys-loop' super-family of evolutionarily related and structurally similar ligand-gated ion channels that also includes the nicotinic acetylcholine, glycine, and 5-HT 3 receptors [1] . The GABA receptor is predominantly expressed in the central nervous system [2, 3] , and forms a chlorideselective transmembrane channel in the post-synaptic sites of nerve terminals. Thus, the GABA A receptor is responsible for fast inhibitory synaptic transmission [4, 5] .
Recent biochemical binding assays produced evidence that ginsenosides might regulate the GABA A receptor.
For example, Kimura et al. [6] showed that ginsenosides differentially regulate [
H]-f1unitrazepam or [
3 H]-muscimol binding to the GABA A receptor in a rat brain membrane fraction. Kim et al. [7] reported that prolonged infusion with ginsenoside Rc, but not ginsenoside Rg 1 , into rat brain elevates [ 3 H]-muscimol binding to the GABA A receptor in a brain region-specific manner. Thus, ginsenosides may regulate the GABA A receptor by affecting ligand affi nity for its receptor, but there is no direct evidence on the regulation of GABA A receptor channel activity by ginsenosides. On the other hand, Choi et al. [8] showed that ginsenoside Rc enhances GABA-mediated ion currents in oocytes expressing the GABA A receptor. These results indicate the possibility that ginsenosides are closely related with GABA A receptor regulation. It is known that protopanaxadiol and protopanaxatriol ginsenosides are metabolized into protopanaxadiol (PPD) and M4, respectively, by gastric juice and intestinal microorganisms after ginseng intake [9] . However, little is known about whether PPD or M4 regulates GABA A receptor channel activity.
In the present study, we examined the effects of ginsenoside metabolites on GABA A receptor channel activity. We injected neuronal human GABA A (α 1 β 1 γ 2s ) receptor cRNAs into Xenopus oocytes and examined the effect of ginsenoside metabolites on the GABA-elicited inward peak currents (I GABA ). Treatment with ginsenoside metabolites inhibited I GABA in a reversible, dose-dependent and non-competitive manner.
MATERIALS AND METHODS

Materials
The ginsenoside metabolites M4 and PPD were provided by the AMBO Institute (Seoul, Korea) (Fig. 1A) . cDNAs for human GABA A receptor subunits were kindly provided by Dr. Whiting (Merck Sharp and Dohme Research Lab., Essex, UK). All other reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA).
Preparation of Xenopus oocytes and microinjection
Xenopus laevis frogs were purchased from Xenopus I (Ann Arbor, MI, USA). Their care and handling were in accordance with the highest standards of institutional guidelines of Konkuk University. For isolation of oocytes, frogs were anesthetized with an aerated solution of 3-amino benzoic acid ethyl ester followed by removal of ovarian follicles. The oocytes were treated with collagenase and then agitated for 2 h in a Ca 2+ -free medium containing 82.5 mM NaCl, 2 mM KCl, 1 mM MgCl 2 , 5 mM HEPES, 2.5 mM sodium pyruvate, 100 units/mL penicillin, and 100 μg/mL streptomycin. Stage V-VI oocytes were collected and stored in ND96 medium (in mM: 96 NaCl, 2 KCl, 1 MgCl 2 , 1.8 CaCl 2 , and 5 HEPES, pH 7.5) supplemented with 50 µg/mL gentamicin. The oocytecontaining solution was maintained at 18°C with continuous gentle shaking and renewed daily. Electrophysiological experiments were performed within 5 to 6 d of oocyte isolation, with ginsenoside metabolites added to the bath. For GABA A receptor activity experiments, each GABA A receptor subunit-encoding cRNA (40 nL) was injected into the animal or vegetal pole of each oocyte one day after isolation, using a 10 µL microdispenser (VWR Scientifi c, San Francisco, CA, USA) fi tted with a tapered glass pipette tip 15 to 20 µm in diameter [8] .
Data recording
A custom-made Plexiglas net chamber was used for two-electrode voltage-clamp recordings as previously reported [8] . The oocytes were impaled with two microelectrodes filled with 3M KCl (0.2-0.7 MΩ), and electrophysiological experiments were carried out at room temperature using an Oocyte Clamp (OC-725C; Warner Instruments, Hamsden, CT, USA). Stimulation and data acquisition were controlled with a pClamp 8 (Axon Instruments, Union City, CA, USA). For most electrophysiological experiments, oocytes were perfused initially with ND96 solution (in mM: 96 NaCl, 3 KCl, 2 CaCl 2 , and 5 HEPES; pH 7.4 with NaOH) and control current recordings were obtained. For most electrophysiological data, the oocytes were clamped at a holding potential of -80 mV. For current and voltage (I-V) relationship, voltage ramps were applied from -100 to +40 mV for 300 ms. In the different membrane-holding potential experiments, the oocytes were clamped at the indicated holding potentials. Linear leak and capacitance currents were corrected by means of the leak subtraction procedure. 
Data analysis
To obtain the concentration-response curve for the effect of ginsenoside metabolites on the inward peak I GABA mediated by the GABA A receptor, the I GABA peak was plotted at different concentrations of GABA and Origin software (Origin, Northampton, MA, USA) was used to fi t the plot to the 
RESULTS AND DISCUSSION
The addition of GABA (10 µM) to the bathing medium induced a large inward current (I GABA ) in oocytes injected with GABA A receptor subunits cRNAs, indicating that the GABA A receptor was functionally expressed (Fig. 1B) . In oocytes expressing GABA A receptor, the treatment of ginsenoside metabolites such as M4 or PPD had no effect. Moreover, co-or pre-treatment with ginsenoside metabolites for 30 s with GABA induced an inhibition of I GABA in a reversible manner ( Fig. 2A, B ; n=15 from three different frogs). As shown in Fig. 2C , M4 more signifi cantly inhibited I GABA than PPD.
In concentration-response experiments with M4 or PPD, co-treatment with M4 and PPD inhibited I GABA in a dose-dependent manner in oocytes expressing the GA-BA A receptor (Fig. 3A, B) . The IC 50 of I GABA by M4 and PPD was 17.1±2.2 and 23.1±8.6 µM, respectively, in oocytes expressing the GABA A receptor (n=9-12 from three different frogs at each point) (Fig. 3B) .
In current-voltage experiments, the membrane potential was held at -80 mV and a voltage ramp was applied from -100 to +40 mV for 300 ms. In the absence of GABA, the inward current at -100 mV was <0.3 µA and the outward current at +40 mV was 0.3-0.5 µA. The addition of GABA to the bathing medium resulted in an increase of the inward current at a potential more negative than -20 mV. In contrast, at a potential more positive than -20 mV, GABA caused a large increase in the outward current. Co-treatment of GABA with M4 or PPD inhibited both inward and outward currents as compared with those induced by GABA treatment alone. The reversal potential was near -20 mV in GABA alone and in GABA + M4 or PPD, which indicates that GABA induces the CI -current [4]. Also, co-treatment of GABA with M4 or PPD did not affect the channel property of the GABA A receptor (Fig. 4A) .
In addition, our results further revealed that the inhibitory effects of M4 and PPD on I GABA in oocytes expressing human GABA A receptors were independent of the membrane holding potential (Fig. 4B) . At membrane holding potentials of −100, −80, −60, −40, and −20 mV, M4 inhibited I GABA by 53.8±2.5%, 52.4±4.0%, 52.8±1.5%, Fig. 2 . Effect of M4 and protopanaxadiol (PPD) on γ-aminobutyric acid (GABA)-induced inward peak current (I GABA ) in oocytes expressing GABA receptor A (GABA A ) receptor. (A) GABA (10 µM) was fi rst applied and then GABA was co-or pre-treated with PPD (100 µM). Co-treatment of PPD with GABA and pre-treatment of PPD before GABA application inhibited I GABA in oocytes expressing α 1 β 1 γ 2s GABA A receptors. (B) GABA (10 µM) was fi rst applied and then GABA was co-or pre-treated with M4 (100 µM). Thus, co-treatment of M4 with GABA and pre-treatment of M4 before GABA application inhibited I GABA in oocytes expressing α 1 β 1 γ 2s GABA A receptors. The resting membrane potential of oocytes was about -35 mV and oocytes were voltage-clamped at a holding potential of -80 mV prior to drug application. Traces are representative of 8-12 separate oocytes from three different frogs. (C) Summary of percent inhibition by M4 and PPD of I GABA was calculated from the average of the peak inward current elicited by GABA alone before M4 or PPD and the peak inward current elicited by GABA alone after co-and pre-treatment of M4 or PPD with GABA. Each point represents the mean±SEM (n=9-12 from three different frogs). Vol. 36, No. 1, 55-60 (2012) 54.1±1.7% and 53.9±2.9%, respectively (n=9-12, from three different frogs). PPD inhibited I GABA by 20.9±1.9%, 23.3±1.4%, 22.1±3.8%, 20.7±1.3% and 21.6±3.0%, same respective order (n=9-12, from three different frogs). To begin studying the mechanism by which M4 or PPD inhibit I GABA in oocytes expressing human GABA A receptors, we analyzed the effect of 100 μM M4 or PPD on the I GABA evoked by different GABA concentrations (Fig. 5A,  B) . Co-treatment of oocytes expressing human GABA A receptors with 100 μM M4 or PPD plus different concentrations of GABA did not signifi cantly shift the dose-response curve of GABA to the right. The EC 50 values were 15.8±2.5, 18.3±2.4 and 15.4±2.6 μM for GABA alone, GABA+M4 and GABA+PPD, respectively, and the Hill coeffi cients were 1.6, 1.5 and 1.7, in the same respective order. Thus, M4 and PPD signifi cantly inhibited the I GABA elicited by 10, 30, and 100 μM of GABA, independent of the GABA concentration (n=6-8 from three different frogs) (Fig. 5A, B) .
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Ginsenosides consist of aglycone and carbohydrate portions. Aglycone is the backbone of the ginsenoside, with a hydrophobic four-ring steroid-like structure that may be non-polar, whereas the carbohydrates on carbons 3, 6, and 20 of the backbone are polar (Fig. 1A) . Therefore, ginsenosides are amphiphilic molecules. In vitro and in vivo studies have shown that ginsenosides administered orally are metabolized and fi nally become an agylcone such as M4 and PPD [9] . These ginsenoside metabolites might also induce apoptosis of cancer cells and play a role as anti-cancer agents [10, 11] , suggesting that ginsenosides are pro-drugs of these metabolites. However, relatively little is known regarding how ginsenoside metabolites regulate ion channel or receptor activity, especially on GABA A receptor.
In the present study, we investigated the effects of ginsenoside metabolites on human GABA A receptors heterologously expressed in Xenopus oocytes. We found that co-or pre-treatment with M4 rather than PPD induced a large inhibition of I GABA in reversible manners, treatment of M4 and PPD inhibited I GABA in oocytes expressing GA-BA A receptors in concentration-dependent manners, and inhibition of I GABA by treatment of M4 or PPD occurred in a voltage-independent and non-competitive manner in oocytes expressing GABA A receptors. These results indicate that the ginsenoside metabolites M4 and PPD might be novel GABA A receptor regulators.
GABA is one of major inhibitory neurotransmitters in the mammalian brain and it has long been known that many neuroactive drugs, such as the benzodiazepines, nonbenzodiazepines, barbiturates, ethanol, neuroactive steroids, anaethetics, and picrotoxin interact with GABA A receptors by binding to modulatory sites of the receptor [12] . Thus, GABA A receptor regulators are clinically important for treatment of various mental dysfunctions. For example, benzodiazepines, which are known to potentiate I GABA , have been used for their anxiolytic, sedative, and myorelaxant effects. However, many unwanted side effects such as amnesic-like effects, ataxia, ethanol and barbiturate potentiation, and tolerance and dependence, appear and result in a reduction in the therapeutic value of benzodiazepines [13] [14] [15] . On the other hand, we have shown that ginsenoside Rc enhances I GABA [8] ; these results are well coupled to the report that some subsets of ginsenosides have anxiolytic-like effects in animal model [16] . Presently, M4 and PPD displayed inhibitory effects on I GABA rather than enhancing effects, indicating the possibility that ginsenoside metabolites are different from intact ginsenosides in the regulation of GABA A receptormediated ion channel regulations.
We have previously reported that ginsenoside metabolites such as compound K (CK), M4, and PPD differentially regulate ion channels and receptors. For example, CK, but not protopanaxatriol (PPT), potently inhibits the voltage-dependent α1G-type Ca 2+ channel [17] . Similarly, we also demonstrated that CK, but not M4 (PPT), inhibits a neuronal Na + (Nav1.2) channel [18] , and that M4, but not CK, inhibits 5-HT 3A receptor-mediated currents [19] . In addition, CK and PPT inhibit α3β4 nicotinic acetylcholine receptor-mediated currents [20] . Recently, we also reported that, although PPD itself does not affect human HERG K + channel activity, it inhibits ginsenoside Rg 3 -mediated decelerating effects of HERG K + channel currents [21] . In the present study, M4 more strongly inhibited GABA A -receptor-mediated ion cur- I GABA of the upper and lower panels were elicited from concentration of 10 µM and 100 µM GABA at a holding potential of -80 mV, respectively. (B) Concentration-response relationships for GABA in the GABA A receptors applied with GABA (1-100 µM) alone or with GABA plus co-treatment of 100 µM M4 or PPD. The I GABA of oocytes expressing the GABA A receptors was measured using the indicated concentration of GABA in the absence (□) or presence (○) of 100 µM M4 or presence (△) of 100 µM PPD. Oocytes were exposed to GABA alone or to GABA with M4 or PPD. Oocytes were voltage-clamped at a holding potential of -80 mV. Each point represents the mean±SEM (n=8-12/group).
rents than PPD. The previous and present fi ndings indicate that ginsenoside metabolites as well as ginsenosides have regulatory effects on voltage-dependent ion channel and receptor activities, but they differentially affect the regulation of ion channels or receptors.
In summary, we have examined the effects of ginsenoside metabolites such as M4 and PPD on human GA-BA A receptor channel activities heterologously expressed in Xenopus oocytes. M4, rather than PPD, mainly inhibits I GABA . Since human GABA A receptors are mainly involved in the modulations of various physiological and pathophysiological activities in the central nervous system, the inhibitory effects of M4 on I GABA could provide a molecular basis for the pharmacological actions of ginsenoside metaobolites in the nervous system.
